Literature DB >> 1851050

Intracarotid chemotherapy with etoposide and cisplatin for malignant brain tumors.

S Madajewicz1, N Chowhan, A Iliya, C Roque, R Beaton, R Davis, S Fertman, A Meek, O Alvarez, M Pampati.   

Abstract

Chemotherapy for tumors of the central nervous system has a limited efficacy presumably because of restricted blood-brain barrier permeability. The advantage of regional intra-arterial administration of anticancer drugs is an increased uptake during the first passage of the drugs through tumor capillaries. Twenty patients with high-grade astrocytomas (HGA) and 28 patients with metastatic brain tumors (MBT) received intracarotid/intravertebral infusion of etoposide and cisplatin. Eight patients with HGA who underwent incomplete resection responded to chemotherapy alone. Four additional patients had complete resection of the tumor. Median survival time of the group (responders and nonresponders) has been 14 months. Twelve patients with MBT responded to chemotherapy alone (six had complete response [CR], and six had partial response [PR]) with a median survival time of 7 months. Intra-arterial chemotherapy (IAC) appears to be effective with acceptable toxicities. Accrual of additional patients is required before a final conclusion can be reached.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1851050     DOI: 10.1002/1097-0142(19910601)67:11<2844::aid-cncr2820671123>3.0.co;2-k

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a phase II study.

Authors:  L S Ashby; W R Shapiro
Journal:  J Neurooncol       Date:  2001-01       Impact factor: 4.130

2.  In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.

Authors:  T Taki; T Ohnishi; N Arita; S Hiraga; T Hayakawa
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

3.  Unusual cervical spinal cord toxicity associated with intra-arterial carboplatin, intra-arterial or intravenous etoposide phosphate, and intravenous cyclophosphamide in conjunction with osmotic blood brain-barrier disruption in the vertebral artery.

Authors:  D Fortin; L D McAllister; G Nesbit; N D Doolittle; M Miner; E J Hanson; E A Neuwelt
Journal:  AJNR Am J Neuroradiol       Date:  1999 Nov-Dec       Impact factor: 3.825

4.  Relationship between drug delivery and the intra-arterial infusion rate of SarCNU in C6 rat brain tumor model.

Authors:  N Takeda; M Diksic
Journal:  J Neurooncol       Date:  1999-02       Impact factor: 4.130

5.  Toxicities related to intraarterial infusion of cisplatin and etoposide in patients with brain tumors.

Authors:  A Tfayli; P Hentschel; S Madajewicz; J Manzione; N Chowhan; R Davis; P Roche; A Iliya; C Roque; A Meek; M Shady
Journal:  J Neurooncol       Date:  1999-03       Impact factor: 4.130

6.  RMP-7 : Potential as an Adjuvant to the Drug Treatment of Brain Tumours.

Authors:  A V Boddy; H D Thomas
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

7.  Intra-arterial cisplatin in malignant brain tumors: incidence and severity of otic toxicity.

Authors:  R Assietti; J J Olson
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

Review 8.  Intra-arterial chemotherapy of primary brain tumors.

Authors:  Herbert B Newton
Journal:  Curr Treat Options Oncol       Date:  2005-11

9.  Impact of intra-arterial chemotherapy including internal carotid artery for advanced paranasal sinus cancers involving the skull base.

Authors:  J Yokoyama; S Ohba; M Fujimaki; T Anzai; M Kojima; K Ikeda; M Suzuki; H Yoshimoto; K Inoue
Journal:  Br J Cancer       Date:  2014-09-25       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.